NCT05569941View on ClinicalTrials.gov

A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABI-4334 Tablet

ABI-4334 Tablet

DRUG

ABI-4334 Placebo

Placebo to ABI-4334 Tablet

Trial Locations (1)

1010

New Zealand Clinical Research, Grafton

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY

NCT05569941 - A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects | Biotech Hunter | Biotech Hunter